Jubilant Pharmova Ltd reports Q2 FY27 revenue of ₹2,370 crore, up 21% YoY, while PAT falls 74% to ₹31 crore
- EBITDA was ₹255 crore, down 27% YoY; margin contracted to 10.7% from 17.8% a year earlier.
- Revenue rose 6.3% sequentially, while EBITDA fell 4.9% and PAT declined 44.6%.
- Raised ₹800 crore through non-convertible debentures for debt refinancing and capital expenditure.